- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01171482
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
An Open Label, Phase 2 Trial Comparing Sorafenib and 5-fluorouracil/Mitomycin in Hepatocellular Carcinoma With Pulmonary Metastasis
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Most HCC patients are diagnosed at advanced stages in Korea, but effective treatment strategies for advanced HCC have not been established. In particular, optimal treatment strategy for extrahepatic as well as intrahepatic recurrences following locoregional therapy (e.g., transarterial chemoembolization, radiofrequency ablation therapy, and percutaneous ethanol injection) is still a challenging issue. Extrahepatic metastasis has been encountered more frequently, being more problematic than before in the management of HCC due to the increased survival with effective locoregional treatments. The lung is the most common site of extrahepatic metastasis and the surgical resection of pulmonary metastatic lesions may result in improved survival in selected patients. Previous studies suggested that aggressive management including resection of the extrahepatic recurrence combined with locoregional therapy for intrahepatic HCC may offer long-term survival in selected patients with recurrent HCC following hepatectomy. Such an aggressive strategy has serious limitation in clinical practice in that extrahepatic recurrence usually present as multiple lesions. Systemic chemotherapy has been one of the most commonly used treatment modalities for patients with multiple extrahepatic metastasis. However, chemotherapy using either a single or combined cytotoxic agents provides only limited benefit for such patients. The aim of this study is to compare the efficacy of sorafenib to 5-fluorouracil/mitomycin in HCC patients with pulmonary metastasis whose intrahepatic tumors had been previously controlled with repeated locoregional therapies before the initiation of systemic chemotherapy.
Outline:
- Experimental arm(the FM group): Patients receive 5-FU IV continuously over 10 hours on day 1~6 and mitomycin IV push on day 1~4. Treatment repeats every 28 days.
- Active Comparator arm(the sorafenib group): Patients will receive 2 tablets of sorafenib (200 mg/tablet) twice daily, orally on a continuous basis.
In all arms, treatment continues in the absence of disease progression or unacceptable toxicity. During the treatment period, patients will have study visits on Day 1 of every cycle (every 4 weeks from start of study drug) and will receive CT/MRI assessment every 2 cycles (every 8 weeks). In the event of radiological progression confined to the liver, e.g. appearance of new nodules in the liver in areas previously not treated by locoregional therapies, patients will then also be treated with locoregional therapies such as TACE or local ablation as long as the they may still benefit from treatment. If patients are no longer amenable to locoregional therapies (in the case of untreatable progression), the study will be stopped and best supportive care be offered. This will be based on the investigator's clinical judgment of the subject's status.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Seoul, Korea, republiek van
- Seoul National University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients with clinical or histological diagnosis of HCC based on the guidelines of the AJCC
- Patients with at least one, bi-dimensionally measurable, pulmonary metastasis without intrahepatic viable tumor (Viable tumor is defined as uptake of contrast agent in the arterial phase of dynamic CT or MRI.)
- Patients who have received previous local therapy treatments (RFA, PEI, cryoablation, surgery, resection) to non-target lesions are eligible
- Age : 20 years to 80 years
- ECOG Performance Status of 0 to 1
- Child-Pugh class A or B (Child-Pugh score 7)
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- Hb ≧ 9 g/dL
- Absolute neutrophil count > 1000/mm3
- Platelet count ≧ 60,000 /mm3
- Adequate clotting function: INR < 1.5
- Hepatic: AST and ALT < 5 X ULN
- Renal: serum creatinine < 1.7mg/dL
- Bilirubin ≦ 3 mg/dL
Exclusion Criteria:
- Patients with diffuse infiltrative type of HCC that are poorly defined
- Presence of hepatic encephalopathy and intractable ascites
- Patients who are on a liver transplant list
- The patient has received prior systemic chemotherapy
- History of organ allograft
- Active clinically serious infections (> grade 2 NCI-CTC version 3.0), including spontaneous bacterial peritonitis
- History of cardiac disease: congestive heart failure > NYHA class 2; active coronary artery disease (myocardial infarction more than 6 months prior to study entry is allowed), cardiac arrhythmias requiring anti-arrhythmic therapy or uncontrolled hypertension and diabetes mellitus
- Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1). Any cancer curatively treated > 3 years prior to entry is permitted
- HIV infection or AIDS-related illness or serious acute or chronic illness (based on medical history)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: The FM group
Patients in the FM group will be administered 5-FU plus mitomycin
|
15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
Andere namen:
4mg/day IV push from day 1 to day 4 every 28 days
|
Actieve vergelijker: The sorafenib group
Patients in the sorafenib group will be administered sorafenib
|
400 mg BID every 28 days
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Progression free survival (PFS)
Tijdsspanne: every 8 weeks
|
every 8 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Time-to-progression (TTP)
Tijdsspanne: every 8 weeks
|
every 8 weeks
|
Objective tumor response rate
Tijdsspanne: Determined by CT scan at the end of every 2 cycles until progressive disease is documented or intolerable toxicity occurs
|
Determined by CT scan at the end of every 2 cycles until progressive disease is documented or intolerable toxicity occurs
|
Adverse event rates and the toxicities
Tijdsspanne: every 4 weeks
|
every 4 weeks
|
Overall survival
Tijdsspanne: every 8 weeks
|
every 8 weeks
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata per site
- Adenocarcinoom
- Neoplasmata, glandulair en epitheel
- Neoplasmata van het spijsverteringsstelsel
- Lever Ziekten
- Lever neoplasmata
- Carcinoom
- Carcinoom, hepatocellulair
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Nucleïnezuursyntheseremmers
- Enzymremmers
- Antimetabolieten, antineoplastische
- Antimetabolieten
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Alkyleringsmiddelen
- Proteïnekinaseremmers
- Antibiotica, antineoplastiek
- Fluoruracil
- Sorafenib
- Mitomycinen
- Mitomycine
Andere studie-ID-nummers
- 07-2010-010
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Carcinoom, hepatocellulair
-
Hospices Civils de LyonWervingKwaadaardige tumoren als Chordoma, Adenoid Cystic Carcinoma en SarcoomFrankrijk
-
CG Oncology, Inc.BeëindigdCarcinoom in Situ | Overgangscelcarcinoom | Blaaskanker | Carcinoma in situ gelijktijdig met papillaire tumorenVerenigde Staten
Klinische onderzoeken op 5-FU
-
Hamamatsu UniversityVoltooidSlokdarmkanker | PlaveiselcelcarcinoomJapan
-
University of Sao PauloLEO PharmaVoltooid
-
Fudan UniversityOnbekend
-
Eastern Hepatobiliary Surgery HospitalVoltooidHepatocellulair carcinoom | Poortader Tumor TrombusChina
-
University Medical Center GroningenAmsterdam UMC, location VUmcVoltooidHoofd-hals plaveiselcelcarcinoomNederland
-
Sol-Gel Technologies, Ltd.VoltooidActinische keratose (AK)Verenigde Staten
-
OnxeoVoltooid
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Glaxo WellcomeVoltooid
-
Taian Cancer HospitalOnbekendSlokdarmcarcinoomChina
-
University of Erlangen-Nürnberg Medical SchoolVoltooid